We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · June 20, 2022

Patient-Reported Outcomes of Avelumab First-Line Maintenance Plus Best Supportive Care vs Best Supportive Care Alone for Advanced Urothelial Carcinoma

European Urology


Additional Info

European Urology
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
Eur Urol 2022 May 30;[EPub Ahead of Print], P Grivas, E Kopyltsov, PJ Su, FX Parnis, SH Park, Y Yamamoto, PC Fong, C Tournigand, MA Climent Duran, A Bamias, C Caserta, J Chang, P Cislo, A di Pietro, J Wang, T Powles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading